Key clinical point: Effectiveness persisted even when one vaccine component was not well matched.
Major finding: Hospitalizations were lowered by 41% in A(H3N2) and A(H1N1)pdm09 viruses.
Study details: Ongoing multisite vaccine effectiveness analysis of 1,792 hospitalized children
Disclosures: The researchers cited multiple sources of financial support for their ongoing work, including Sanofi, Quidel, Moderna, Karius, GlaxoSmithKline, Merck, AstraZeneca, and Pfizer. Funding for this study was supported by the Centers for Disease Control and Prevention.
Campbell AP et al. Pediatrics. 2020;146(5):e20201368.